Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?

Details

Ressource 1Download: serval:BIB_FD087940F734.P001 (306.44 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_FD087940F734
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Evaluation of antiarrhythmic drug efficacy in patients with an ICD. Unlimited potential or replete with complexity and problems?
Journal
European Heart Journal
Author(s)
Pratt  C. M., Camm  A. J., Bigger, J. T., Jr. , Breithardt  G., Campbell  R. W., Epstein  A. E., Kappenberger  L. J., Kuck  K., Pocock  S., Saksena  S., Waldo  A. L.
ISSN
0195-668X (Print)
Publication state
Published
Issued date
11/1999
Volume
20
Number
21
Pages
1538-52
Notes
Journal Article
Review --- Old month value: Nov
Abstract
A report from a Study group, proposed by A. J. Camm, London, of the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology; co-sponsored by the North American Society of Pacing and Electrophysiology. The Study Group was convened on 29 August 1997 at Saltsjobaden, near Stockholm. The meeting was chaired by A. J. Camm, London, and C. M. Pratt, Houston. Based on the presentation and discussions, a first draft of the documents was prepared by C. Pratt and J. Camm which was then circulated to all members three times for their review. All members of the Study Group approved the final manuscript. This report represents the opinion of the members of this Study Group and does not necessarily reflect the official position of either society.The meeting of the Study Group was made possible by unrestricted educational grants from Medtronic, Guidant, Proctor & Gamble, Berlex and Sanofi.Also, presented, in part, at the Cardio-Renal Drugs Advisory Board meeting of the Food and Drug Administration, Bethesda, Maryland, on 30 April 1999.
Keywords
Anti-Arrhythmia Agents/*therapeutic use Arrhythmia/drug therapy/etiology/*therapy Cause of Death Clinical Protocols *Clinical Trials *Defibrillators, Implantable Evaluation Studies Humans Patient Selection Tachycardia/drug therapy Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
15/02/2008 12:29
Last modification date
25/09/2019 7:11
Usage data